Waiv, previously operating as Owkin Dx, will expand global access to a pipeline of AI-driven digital pathology and multimodal tests for cancer.

The firm said it expects to file an investigational new drug application for the autologous CAR T-cell therapy TPST-2003 in the US by the end of the year.

The firm is hoping to outline a potential path to accelerated approval for SGT-003 as it gears up to launch a randomized, controlled Phase III trial.

NEW YORK – Cbio will begin a European Phase I/II trial of its autologous T-cell therapy novoleucel for patients with late-stage cervical cancer, with initial results expected by the end of the year.

The firm previously held rights to develop and commercialize ERAS-0015 in territories outside of China, Hong Kong, and Macau.

The $550 million convertible senior notes offering was upsized from a previously announced offering of $350 million.

The three-year collaboration will try to identify biomarkers that can eventually be used for targeted diagnostics and therapies.

The new financing was led by Venrock Healthcare Capital Partners with participation from other new and existing investors.

NEW YORK – The US Food and Drug Administration on Tuesday approved GSK's Wellcovorin (leucovorin calcium) as a treatment for adult and pediatric patients with cerebral folate deficiency who harbor ...

The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.

NEW YORK – Ohio State University researchers are using urine samples to understand bladder cancer patients' tumor microenvironments in several ongoing clinical trials, and they're confident the method ...